热门资讯> 正文
Aditext以3600万美元的优先股交易收购Telecite Proteomics;股价下跌
2026-03-14 02:25
- Aditxt (ADTX) acquired 100% of Ignite Proteomics from IMAC Holdings plus $475K in cash.
- The deal consideration was 36,000 Series A-2 convertible preferred shares valued at $36M (stated value $1,000 each).
- The preferred shares are convertible into common stock at $2.731 per share, subject to adjustments and a 9.99% ownership cap.
- Aditxt also issued $3.19M in promissory notes (9-month maturity) with $2.875M funded at closing and 6% interest (12% upon default).
- The company said the acquisition restores its stockholders’ equity above $2.5M, helping it regain compliance with Nasdaq.
- ADTX shares tumble over 37%.
More on Aditx Therapeutics
- Financial information for Aditx Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
